Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Reduced by Hartford Investment Management Co.

Hartford Investment Management Co. lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,631 shares of the pharmaceutical company’s stock after selling 1,662 shares during the quarter. Hartford Investment Management Co.’s holdings in Vertex Pharmaceuticals were worth $5,083,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of VRTX. Oregon Public Employees Retirement Fund grew its stake in Vertex Pharmaceuticals by 16,530.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock worth $28,000 after purchasing an additional 4,583,156 shares in the last quarter. FMR LLC lifted its holdings in Vertex Pharmaceuticals by 13.3% during the 4th quarter. FMR LLC now owns 20,483,109 shares of the pharmaceutical company’s stock worth $3,394,256,000 after buying an additional 2,411,631 shares during the last quarter. Norges Bank purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth about $380,584,000. Jennison Associates LLC lifted its holdings in Vertex Pharmaceuticals by 11.9% during the 4th quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock worth $1,150,296,000 after buying an additional 739,128 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in Vertex Pharmaceuticals by 74.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 601,559 shares of the pharmaceutical company’s stock worth $99,685,000 after buying an additional 257,683 shares during the last quarter. Institutional investors own 94.92% of the company’s stock.

NASDAQ:VRTX traded up $3.25 during trading hours on Wednesday, reaching $172.37. 1,060,810 shares of the company traded hands, compared to its average volume of 1,383,313. The stock has a market cap of $43.22 billion, a PE ratio of 60.91, a price-to-earnings-growth ratio of 2.45 and a beta of 1.56. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78. Vertex Pharmaceuticals Incorporated has a 1-year low of $144.07 and a 1-year high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.49. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The company had revenue of $857.00 million for the quarter, compared to analyst estimates of $853.00 million. During the same quarter in the prior year, the company posted $0.76 EPS. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 3.06 earnings per share for the current fiscal year.

A number of analysts have issued reports on VRTX shares. BidaskClub raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 16th. Cowen reissued a “buy” rating and issued a $220.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, March 6th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $209.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, May 1st. Needham & Company LLC reissued a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, May 1st. Finally, ValuEngine raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $203.62.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 5,624 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $181.75, for a total transaction of $1,022,162.00. Following the transaction, the executive vice president now owns 36,272 shares of the company’s stock, valued at approximately $6,592,436. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey M. Leiden sold 33,058 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $175.01, for a total value of $5,785,480.58. Following the completion of the transaction, the chief executive officer now directly owns 136,953 shares in the company, valued at $23,968,144.53. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,247 shares of company stock worth $8,998,147. Corporate insiders own 0.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Sundance Herald and is owned by of Sundance Herald. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://sundanceherald.com/2019/05/22/hartford-investment-management-co-lowers-stake-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Story: Derivative

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply